T1	p 198 242	zoster ( HZ ) and postherpetic neuralgia and
T2	p 258 297	for individuals > or =60 years of age .
T3	p 473 571	in subjects > or =50 years of age . Subjects with a negative history for HZ were randomized 1:1 to
T4	p 613 672	Enrollment was stratified 1:2 by age ( 50 to 59 years and >
T5	p 676 685	=60 years
T6	i 98 129	refrigerator-stable formulation
T7	i 133 143	Zostavax .
T8	i 148 164	vaccine Zostavax
T9	i 357 414	refrigerator-stable formulation ( Zostavax refrigerated )
T10	i 441 472	formulation ( Zostavax frozen )
T11	i 599 612	formulation .
T12	i 741 757	Varicella-zoster
T13	i 1870 1889	refrigerator-stable
T14	i 1905 1913	Zostavax
T15	o 690 696	Safety
T16	o 741 790	Varicella-zoster virus ( VZV ) antibody responses
T17	o 810 850	glycoprotein enzyme-linked immunosorbent
T18	o 902 943	VZV antibody geometric mean titer ( GMT ;
T19	o 959 997	VZV antibody geometric mean rise ( GMR
T20	o 1021 1089	the incidence of vaccine-related serious adverse experiences ( AEs )
T21	o 1186 1190	GMTs
T22	o 1249 1316	estimated GMT ratio ( refrigerated formulation/frozen formulation )
T23	o 1424 1451	vaccine-related serious AEs
T24	o 1492 1507	safety profiles
T25	o 1557 1590	frequencies of injection-site AEs
T26	o 1747 1759	systemic AEs
T27	o 1932 1938	safety